4726.TWO Mycenax Biotech

Healthcare Biotechnology Taiwan OTC Exchange
20.70 TWD
Close of Nov 6, 2026
19.95 37.00
Market cap
TWD 4.29B
P/E
-
P/B
3.12x
ROE
-28.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4726.TWO undervalued?

Graham number

The Graham number of Mycenax Biotech cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mycenax Biotech fundamental analysis

No fundamental analysis for Mycenax Biotech yet.

Mycenax Biotech stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, a…

Full company profile